INSM:NSD-Insmed Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 71.24

Change

+1.73 (+2.49)%

Market Cap

USD 12.52B

Volume

1.55M

Analyst Target

USD 45.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+12.95 (+2.71%)

USD 126.52B
REGN Regeneron Pharmaceuticals Inc

+24.00 (+4.27%)

USD 69.68B
ARGX argenx NV ADR

+4.17 (+0.70%)

USD 35.43B
ALNY Alnylam Pharmaceuticals Inc

+4.00 (+1.72%)

USD 30.51B
ONC BeiGene, Ltd.

+23.55 (+10.27%)

USD 26.35B
RPRX Royalty Pharma Plc

N/A

USD 19.31B
SMMT Summit Therapeutics PLC

+2.13 (+8.45%)

USD 14.57B
INCY Incyte Corporation

+0.58 (+1.02%)

USD 11.72B
BMRN Biomarin Pharmaceutical Inc

+2.85 (+4.86%)

USD 11.50B
MRNA Moderna Inc

+0.61 (+2.43%)

USD 9.91B

ETFs Containing INSM

CURE:AU ETFS S&P Biotech ETF 2.65 % 0.00 %

-0.67 (-2.82%)

USD 0.04B
RSSL:AU Global X Russell 2000 Etf 1.36 % 0.00 %

-0.23 (-2.82%)

N/A
VRTGX Vanguard Russell 2000 Gro.. 1.07 % 0.00 %

+8.92 (+-2.82%)

USD 1.19B
R2US:PA SSgA SPDR ETFs Europe II .. 0.55 % 0.00 %

-0.07 (-2.82%)

USD 4.13B
RSSL Global X Funds 0.55 % 0.00 %

+1.92 (+-2.82%)

USD 1.46B
R2US:SW SPDR® Russell 2000 US Sm.. 0.54 % 0.00 %

-0.43 (-2.82%)

USD 4.18B
XRS2:SW Xtrackers Russell 2000 UC.. 0.54 % 0.00 %

-1.45 (-2.82%)

USD 1.82B
VRTIX Vanguard Russell 2000 Ind.. 0.54 % 0.00 %

+7.67 (+-2.82%)

USD 10.02B
ITWO Proshares Russell 2000 Hi.. 0.47 % 0.00 %

+0.88 (+-2.82%)

USD 0.04B
UWM ProShares Ultra Russell20.. 0.45 % 0.95 %

+1.48 (+-2.82%)

USD 0.26B
VISM:AU Vanguard MSCI Internation.. 0.18 % 0.00 %

-1.24 (-2.82%)

USD 0.29B
HDG ProShares Hedge Replicati.. 0.07 % 0.95 %

+0.46 (+-2.82%)

USD 0.02B
IWM iShares Russell 2000 ETF 0.00 % 0.19 %

+4.73 (+-2.82%)

N/A
JKJ 0.00 % 0.25 %

N/A

N/A
JKK 0.00 % 0.30 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

+3.98 (+-2.82%)

USD 0.53B
BTEC 0.00 % 0.42 %

N/A

N/A
URTY ProShares UltraPro Russel.. 0.00 % 0.95 %

+1.97 (+-2.82%)

USD 0.33B
VTWG Vanguard Russell 2000 Gro.. 0.00 % 0.20 %

+4.58 (+-2.82%)

USD 0.94B
VTWO Vanguard Russell 2000 Ind.. 0.00 % 0.15 %

+1.96 (+-2.82%)

USD 11.00B
R2SC:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

-0.06 (-2.82%)

USD 4.13B
R2US:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

+0.26 (+-2.82%)

USD 4.13B
XRSG:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

-33.50 (-2.82%)

USD 1.80B
XRSU:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

+1.96 (+-2.82%)

USD 1.80B
XRS2:F Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

-2.65 (-2.82%)

USD 1.19B
ZPRR:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

-0.33 (-2.82%)

USD 2.91B
XRS2:XETRA Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

-1.15 (-2.82%)

N/A
ZPRR:XETRA SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

-0.17 (-2.82%)

N/A
ISCG iShares Morningstar Small.. 0.00 % 0.00 %

+1.10 (+-2.82%)

USD 0.61B
ISCB iShares Morningstar Small.. 0.00 % 0.00 %

+1.32 (+-2.82%)

USD 0.19B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.19% 81% B- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.19% 81% B- 81% B-
Trailing 12 Months  
Capital Gain 181.92% 97% N/A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 181.92% 97% N/A 97% N/A
Trailing 5 Years  
Capital Gain 243.33% 94% A 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 243.33% 94% A 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 398.77% 92% A 97% N/A
Dividend Return 398.77% 92% A 97% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 2,018.79% 9% A- 3% F
Risk Adjusted Return 19.75% 80% B- 55% F
Market Capitalization 12.52B 99% N/A 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector